PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02557321 |
Recruitment Status
:
Recruiting
First Posted
: September 23, 2015
Last Update Posted
: January 16, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Melanoma | Drug: PV-10 Drug: Pembrolizumab | Phase 1 Phase 2 |
Up to 24 eligible subjects will be enrolled in the Phase 1b portion of the study. Each subject in this cohort will receive the combination of IL PV-10 and pembrolizumab.
A total of an estimated 120 eligible subjects will be randomized in a 1:1 ratio to the two treatment arms (i.e., PV-10 + pembrolizumab or pembrolizumab alone) in the Phase 2 portion of the study. This number of subjects may be modified based on emerging evidence of preliminary efficacy and effect size from the Phase 1b portion of the study.
Subjects assigned to receive PV-10 in Phase 1b and 2 will receive initial IL PV-10 to their injectable cutaneous and subcutaneous lesions commencing on study Day 1 for up to 13 weeks (i.e., investigational Treatment Phase of the study). PV-10 may be re-administered at 21-day (3-week) intervals during the Treatment Phase of the study to any remaining, uninjected cutaneous and subcutaneous lesions until all injectable cutaneous and subcutaneous lesions have been injected. Lesions that fail to exhibit complete ablation may be re-injected on this schedule.
Pembrolizumab will be administered at 21-day (3-week) intervals per prescribing information (label) commencing on study Day 1 for up to 24 months or until disease progression, toxicity requiring discontinuation of study treatment or study termination.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 144 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination With Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma |
Study Start Date : | October 2015 |
Estimated Primary Completion Date : | November 2018 |
Estimated Study Completion Date : | November 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Phase 1b
PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
|
Drug: PV-10
PV-10 will be administered by intralesional injection every 3 weeks at Day 1 (Week 1), Week 4, Week 7, Week 10 and Week 13
Other Name: Rose Bengal Disodium
Drug: Pembrolizumab
Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)
|
Experimental: Phase 2 (Arm 1)
PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
|
Drug: PV-10
PV-10 will be administered by intralesional injection every 3 weeks at Day 1 (Week 1), Week 4, Week 7, Week 10 and Week 13
Other Name: Rose Bengal Disodium
Drug: Pembrolizumab
Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)
|
Active Comparator: Phase 2 (Arm 2)
Pembrolizumab (2 mg/kg every 3 weeks)
|
Drug: Pembrolizumab
Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)
|
- Safety and tolerability of the combination regimen assessed by adverse events (AEs) [ Time Frame: Start of treatment until 4 weeks after final administration of PV-10 ]Phase 1b: Safety and tolerability of the combination regimen will be assessed by monitoring the frequency, duration, severity and attribution of adverse events (AEs) and toxicities requiring discontinuation of study treatment, and evaluating changes in laboratory values and vital signs
- Progression Free Survival (PFS) [ Time Frame: Up to 24 months from initiation of study treatment ]Phase 2: Response evaluated by blinded independent review committee assessment per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1
- Progression Free Survival (PFS) [ Time Frame: Up to 24 months from initiation of study treatment ]Phase 1b: Response evaluated per RECIST 1.1
- Objective Response Rate (ORR) [ Time Frame: Up to 24 months from initiation of study treatment ]Phase 1b and 2: Response evaluated per RECIST 1.1
- Change in immune biomarkers [ Time Frame: Up to 28 weeks from initiation of study treatment ]Phase 1b: Peripheral Blood Mononuclear Cells (PBMCs) assessed vs. baseline values for changes in T cell populations
- Overall Survival (OS) [ Time Frame: 24 months from initiation of study treatment for last subject randomized ]Phase 1b and 2
- Safety and tolerability of the combination regimen assessed by adverse events (AEs) [ Time Frame: Start of treatment until 4 weeks after final administration of PV-10 ]Phase 2: Safety and tolerability of the combination regimen will be assessed by monitoring the frequency, duration, severity and attribution of adverse events (AEs) and toxicities requiring discontinuation of study treatment, and evaluating changes in laboratory values and vital signs

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 18 years or older, male or female.
- Histologically or cytologically confirmed diagnosis of melanoma.
- Stage IV melanoma for which surgery is not recommended.
- At least 1 cutaneous or subcutaneous Injectable Lesion with longest diameter at least 5 mm.
- A minimum of 1 measurable Target Lesion (i.e., ≥ 10 mm longest diameter).
- Performance Status: Eastern Cooperative Oncology Group (ECOG) 0-1.
-
Clinical Laboratories:
- absolute neutrophil count (ANC) ≥ 1.5 x 109/L and platelet count ≥100 x 109/L
- estimated creatinine clearance (CrCl, by Cockcroft-Gault formula) or estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2
- total bilirubin ≤ 3 times the upper limit of normal (ULN)
- aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP) ≤ 5 times the upper limit of normal (ULN)
- Thyroid function abnormality ≤ Common Toxicity Criteria for Adverse Effects (CTCAE) Grade 2.
Exclusion Criteria:
-
Untreated or clinically active melanoma brain metastases.
- Subjects with ≤ 3 brain metastases and each ≤ 1 cm size that were treated with either surgical resection and/or radiation therapy are eligible for study participation provided (a) there is no evidence of progressive central nervous system (CNS) disease on brain imaging at least 30 days after definitive treatment and (b) the subject is not taking prednisone at >10 mg or equivalent daily.
- Subjects with > 1 cm or > 3 in number treated brain metastases are eligible for study participation provided (a) there is no evidence of progressive CNS disease on brain imaging at least 90 days after treatment with surgery and/or radiation therapy and (b) if the subject is not taking prednisone at >10 mg or equivalent daily.
-
Prior treatment with PV-10 or any anti-PD-1 antibody
- Subjects previously treated with any anti-PD-L1 antibody are eligible for study participation).
- Prior cancer therapy or anti-cancer vaccine within 4 weeks of initial study treatment.
- Known sensitivity to any of the products or components to be administered during dosing.
-
Concurrent or Intercurrent Illness:
- History or evidence of symptomatic autoimmune pneumonitis, glomerulonephritis, vasculitis, or other systemic autoimmune disease.
- Evidence of clinically significant immunosuppression.
- Impaired wound healing or other extremity complications due to severe or uncontrolled diabetes mellitus in subjects whose Injectable Lesions are located in an extremity.
- Severe peripheral vascular disease (i.e., severe claudication [pain occurring after less than 200 meters of walking], rest pain, ischemic ulceration or gangrene) in subjects whose Injectable Lesions are located in an extremity.
- Significant concurrent or intercurrent illness, psychiatric disorders, or alcohol or chemical dependence that would, in the opinion of the Investigator, compromise the subject's safety or compliance or interfere with interpretation of study results.
- Uncontrolled thyroid disease or cystic fibrosis.
- Clinically significant acute or unstable cardiovascular, cerebrovascular (stroke), renal, gastrointestinal, pulmonary, immunological, endocrine, or central nervous system disorders.
- Malignancy other than melanoma within 2 years of enrollment except for: adequately treated (i.e., with curative intent) basal or squamous cell carcinoma, in situ carcinoma of the cervix, in situ ductal adenocarcinoma of the breast, in situ prostate cancer, or limited stage bladder cancer.
-
Pregnancy:
- Female subjects who are pregnant or lactating.
- Female subjects who have positive serum pregnancy test taken within 14 days of initiation of study treatment.
- Female subjects of childbearing potential (defined as having a menstrual cycle within the past 12 months and not having had a surgical procedure to accomplish sterilization) who are not using highly effective contraception (e.g., oral contraceptives, intrauterine devices, double barrier methods such as condoms and diaphragms, abstinence or equivalent measures).
- Male subjects who are unwilling to use acceptable method of effective contraception.
- Subjects unable to comprehend and give informed consent are excluded.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02557321
Contact: Eric Wachter, Ph.D. | 865-769-4011 ext 23 | wachter@pvct.com |
United States, California | |
Cedars-Sinai Medical Center | Recruiting |
Los Angeles, California, United States, 90048 | |
Contact: Jaime Richardson, RN, BSN, OCN 310-423-2133 Jaime.Richardson@cshs.org | |
Principal Investigator: Richard Essner, MD | |
United States, Florida | |
Moffitt Cancer Center | Recruiting |
Tampa, Florida, United States, 33612 | |
Contact: Gina Arnone 813-745-2493 Gina.Arnone@moffitt.org | |
Principal Investigator: Jonathan Zager, MD | |
United States, New Hampshire | |
Dartmouth-Hitchcock Medical Center | Recruiting |
Lebanon, New Hampshire, United States, 03756 | |
Contact: Tanya M Perry, BS, CCRC 603-650-6056 Tanya.M.Perry@hitchcock.org | |
Principal Investigator: Keisuke Shirai, MD | |
United States, Pennsylvania | |
St Luke's University Hospital and Health Network | Recruiting |
Easton, Pennsylvania, United States, 18045 | |
Contact: Robyn Rex 484-503-4152 Robyn.Rex@sluhn.org | |
Principal Investigator: Sanjiv Agarwala, MD | |
United States, Texas | |
MD Anderson Cancer Center | Recruiting |
Houston, Texas, United States, 77230 | |
Contact: Stephy Charamkattu 713-563-2457 SSCharamkattu@mdanderson.org | |
Principal Investigator: Merrick I Ross, MD | |
Australia, Queensland | |
Princess Alexandra Hospital | Recruiting |
Brisbane, Queensland, Australia, 4102 | |
Contact: Janine Thomas Janine.thomas@mater.uq.edu.au | |
Principal Investigator: Mark Smithers, MB BS, FRACS | |
Principal Investigator: Victoria Atkinson, MB BS, FRACP |
Study Director: | Eric Wachter, Ph.D. | Provectus Pharmaceuticals, Inc. |
Responsible Party: | Provectus Biopharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT02557321 History of Changes |
Other Study ID Numbers: |
PV-10-MM-1201 |
First Posted: | September 23, 2015 Key Record Dates |
Last Update Posted: | January 16, 2018 |
Last Verified: | January 2018 |
Additional relevant MeSH terms:
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type |
Neoplasms Neoplasms, Nerve Tissue Nevi and Melanomas Pembrolizumab Antineoplastic Agents |